Adiponectin in Heart Failure

References

• Ponikowski P , AnkerS, AlHabibKet al. Heart failure: preventing disease and death worldwide. ESC Heart Fail., 1(1), 4–25 (2014).
   PubMedGoogle Scholar
• Ceia F , FonsecaC, MotaTet al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur. J. Heart Fail., 4(4), 531–539 (2002).
   PubMed Web of Science ®Google Scholar
• Mozaffarian D , BenjaminE, GoAet al. Heart disease and stroke statistics—2016 update. Circulation, 133(4), e38–e360 (2016).
   PubMed Web of Science ®Google Scholar
• Baltrūnienė V , BironaitėD, KažukauskienėIet al. The role of serum adiponectin for outcome prediction in patients with dilated cardiomyopathy and advanced heart failure. BioMed Res. Int., 2017, 1–13 (2017).
   Web of Science ®Google Scholar
• Huang Y , LinY, ZhangSet al. Circulating omentin-1 levels are decreased in dilated cardiomyopathy patients with overt heart failure. Dis. Markers, 2016, 1–7 (2016).
   Web of Science ®Google Scholar
• Szabó T , ScherbakovN, SandekAet al. Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status and prognosis. Nutr. Metab. Cardiovasc., 24(1), 50–56 (2014).
   PubMed Web of Science ®Google Scholar
• Shinmura K . Is adiponectin a bystander or a mediator in heart failure? The tangled thread of a good-natured adipokine in aging and cardiovascular disease. Heart Fail. Rev., 15(5), 457–466 (2010).
   PubMed Web of Science ®Google Scholar
• Wannamethee SG , WhincupPH, LennonL, SattarN. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch. Intern. Med., 167(14), 1510–1517 (2007).
   PubMedGoogle Scholar
• Shibata R , OuchiN, MuroharaT. Adiponectin and Cardiovascular Disease. Circulation, 73(4), 608–614 (2009).
   Web of Science ®Google Scholar
• Menzaghi C , TrischittaV. The adiponectin paradox for all-cause and cardiovascular mortality. Diabetes, 67(1), 12–22 (2018).
   PubMed Web of Science ®Google Scholar
• Khan R , KatoT, ChokshiAet al. Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure. Circ. Heart Fail., 5(3), 340–348 (2012).
   PubMed Web of Science ®Google Scholar
• Takano H , ObataJ, KodamaYet al. Adiponectin is released from the heart in patients with heart failure. Int. J. Cardiol., 132(2), 221–226 (2009).
   PubMed Web of Science ®Google Scholar
• Scherer P , WilliamsS, FoglianoM, BaldiniG, LodishH. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem., 270(45), 26746–26749 (1995).
   PubMed Web of Science ®Google Scholar
• Wang Z , SchererP. Adiponectin, the past two decades. J. Mol. Cell. Biol., 8(2), 93–100 (2016).
   PubMed Web of Science ®Google Scholar
• Hug C , WangJ, AhmadN, BoganJ, TsaoT, LodishH. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl Acad. Sci. USA, 101(28), 10308–10313 (2004).
   PubMed Web of Science ®Google Scholar
• Yamauchi T , KamonJ, ItoYet al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 423(6941), 762–769 (2003).
   PubMed Web of Science ®Google Scholar
• Yamauchi T , NioY, MakiTet al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med., 13(3), 332–339 (2007).
   PubMed Web of Science ®Google Scholar
• Holland W , MillerR, WangZet al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med., 17(1), 55–63 (2010).
   PubMed Web of Science ®Google Scholar
• Winder WW , HardieDG. AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes. Am. J. Physiol-Endoc., 277(1), E1–10 (1999).
   PubMed Web of Science ®Google Scholar
• Wang ZV , SchererPE. Adiponectin, cardiovascular function and hypertension. Hypertension, 51(1), 8–14 (2008).
   PubMed Web of Science ®Google Scholar
• Agra RM , Fernández-TrasancosÁ, Díaz-RodríguezEet al. Nutrients restriction upregulates adiponectin in epicardial or subcutaneous adipose tissue: impact in de novo heart failure patients. Int. J. Med. Sci., 15(5), 417–424 (2018).
   PubMed Web of Science ®Google Scholar
• Okamoto Y , KiharaS, OuchiNet al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation, 106(22), 2767–7 (2002).
   PubMed Web of Science ®Google Scholar
• Kobashi C , UrakazeM, KishidaMet al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res., 97(12), 1245–1252 (2005).
   PubMed Web of Science ®Google Scholar
• Ouchi N , KiharaS, AritaYet al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation, 102(11), 1296–1301 (2000).
   PubMed Web of Science ®Google Scholar
• Iacobellis G , PistilliD, GucciardoMet al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine, 29(6), 251–255 (2005).
   PubMed Web of Science ®Google Scholar
• Song Y , SongF, WuC, HongYX, LiG. The roles of epicardial adipose tissue in heart failure. Heart Fail. Rev.https://doi.org/10.1007/s10741-020-09997-x ( Epub ahead of print).
   Web of Science ®Google Scholar
• Qi Y , TakahashiN, HilemanSMet al. Adiponectin acts in the brain to decrease body weight. Nat. Med., 10(5), 524–529 (2004).
   PubMed Web of Science ®Google Scholar
• Rutkowski JM , WangZV, ParkASDet al. Adiponectin promotes functional recovery after podocyte ablation. J. Am. Soc. Nephrol., 24(2), 268–282 (2013).
   PubMed Web of Science ®Google Scholar
• Chaurasia B , SummersSA. Ceramides - lipotoxic inducers of metabolic disorders. Trends Endocrinol. Metab., 26(10), 538–550 (2015).
   PubMed Web of Science ®Google Scholar
• Szczurek W , Szyguła-JurkiewiczB. Oxidative stress and inflammatory markers – the future of heart failure diagnostics?Kardiochir. Torakochirurgia Pol., 2, 145–149 (2015).
   Google Scholar
• Shibata R , OuchiN, KiharaS, SatoK, FunahashiT, WalshK. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J. Biol. Chem., 279(27), 28670–28674 (2004).
   PubMed Web of Science ®Google Scholar
• Ouchi N , KobayashiH, KiharaSet al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem., 279(2), 1304–1309 (2004).
   PubMed Web of Science ®Google Scholar
• Kobayashi H , OuchiN, KiharaSet al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res., 94(4), e27–31 (2004).
   PubMed Web of Science ®Google Scholar
• Chen H , MontagnaniM, FunahashiT, ShimomuraI, QuonMJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem., 278, 45021–45026 (2003).
   PubMed Web of Science ®Google Scholar
• Cheng KK , LamKS, WangYet al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes, 56(5), 1387–1394 (2007).
   PubMed Web of Science ®Google Scholar
• Parker-Duffen JL , NakamuraK, SilverMet al. T-cadherin is essential for adiponectin-mediated revascularization. J. Biol. Chem., 288(34), 24886–24897 (2013).
   PubMed Web of Science ®Google Scholar
• Denzel MS , ScimiaMC, ZumsteinPM, WalshK, Ruiz-LozanoP, RanschtB. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J. Clin. Invest., 120(12), 4342–4352 (2010).
   PubMed Web of Science ®Google Scholar
• Shibata R , SatoK, PimentelDRet al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med., 11(10), 1096–1103 (2005).
   PubMed Web of Science ®Google Scholar
• Piñeiro R , IglesiasMJ, GallegoRet al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett., 579(23), 5163–5169 (2005).
   PubMed Web of Science ®Google Scholar
• Fujioka D , KawabataKI, SaitoYet al. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am. J. Physiol. Heart Circ. Physiol., 290, H2409–H2416 (2006).
   PubMed Web of Science ®Google Scholar
• Fujita K , MaedaN, SonodaMet al. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler. Thromb. Vasc. Biol., 28(5), 863–870 (2008).
   PubMed Web of Science ®Google Scholar
• Walkey AJ , RiceTW, KonterJet al. Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure. Crit. Care Med., 38(12), 2329–2334 (2010).
   PubMed Web of Science ®Google Scholar
• Kistorp C , FaberJ, GalatiusSet al. Plasma adiponectin, body mass index and mortality in patients with chronic heart failure. Circulation, 112(12), 1756–1762 (2005).
   PubMed Web of Science ®Google Scholar
• Beatty AL , ZhangMH, KuIA, NaB, SchillerNB, WhooleyMA. Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. Atherosclerosis, 220(2), 587–592 (2012).
   PubMed Web of Science ®Google Scholar
• Arita Y , KiharaS, OuchiNet al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun., 257(1), 79–83 (1999).
   PubMed Web of Science ®Google Scholar
• Nakamura T , FunayamaH, KuboNet al. Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. Circ. J., 70, 1557–1562 (2006).
   PubMed Web of Science ®Google Scholar
• Kung T , SzabóT, SpringerJ, DoehnerW, AnkerSD, HaehlingSV. Cachexia in heart disease: highlights from the ESC 2010. J. Cachexia Sarcopenia Muscle, 2(1), 63–69 (2011).
   PubMed Web of Science ®Google Scholar
• Masson S , GoriF, LatiniRet al. GISSI-HF Investigators. Adiponectin in chronic heart failure: influence of diabetes and genetic variants. Eur. J. Clin. Invest., 41(12), 1330–1338 (2011).
   PubMed Web of Science ®Google Scholar
• Ortega Moreno L , CopettiM, FontanaAet al. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. Cardiovasc. Diabetol., 15, 17 (2016).
   PubMed Web of Science ®Google Scholar
• Ding M , RzucidloEM, DaveyJCet al. Adiponectin in the heart and vascular system. Vitam. Horm., 90, 289–319 (2012).
   PubMed Web of Science ®Google Scholar
• Lo MM , MitsnefesM. Adiponectin, cardiovascular disease, chronic kidney disease: emerging data on complex interactions. Pediatr. Nephrol., 27(4), 521–527 (2012).
   PubMed Web of Science ®Google Scholar
• Biolo A , ShibataR, OuchiNet al. Determinants of adiponectin levels in patients with chronic systolic heart failure. Am. J. Cardiol., 105(8), 1147–1152 (2010).
   PubMed Web of Science ®Google Scholar
• George J , PatalS, WexlerDet al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart, 92(10), 1420–1424 (2006).
   PubMed Web of Science ®Google Scholar
• Ohara T , HashimuraK, AsakuraMet al. Dynamic changes in plasma total and high molecular weight adiponectin levels in acute heart failure. J. Cardiol., 58(2), 181–190 (2011).
   PubMed Web of Science ®Google Scholar
• Tsukamoto O , FujitaM, KatoMet al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J. Am. Coll. Cardiol., 53(22), 2070–2077 (2009).
   PubMed Web of Science ®Google Scholar
• Masuch A , PietznerM, BahlsMet al. Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP. Cardiovasc. Diabetol., 17(1), 120 (2018).
   PubMedGoogle Scholar
• Uriel N , NakaY, ColomboPCet al. Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur. J. Heart Fail., 13(2), 195–199 (2011).
   PubMed Web of Science ®Google Scholar
• Khawaja T , ChokshiA, JiRet al. Ventricular assist device implantation improves skeletal muscle function, oxidative capacity and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure. J. Cachexia Sarcopenia Muscle, 5(4), 297–305 (2014).
   PubMed Web of Science ®Google Scholar